CFOR on OTC

OpGen (United States)

Logo: opgen.com3

American medical laboratories services company based in Gaithersburg.1

Price unavailable

Last updated Oct 18, 2026.

Overview

2002Founded1

Compare with AMERICAN SHARED HOSPITAL SERVICES, Psychemedics Corporation or Exagen Inc., or pick any stock.

  • TickerCFOR on OTC1
  • IndustryServices-Medical Laboratories1
  • HeadquartersGaithersburg1
  • Websiteopgen.com
  • Incorporated inDE4
  • Business addressUnit L33A-7, Tower A, Menara Uoa Bangsar, No. 5, Jalan Bangsar Utama 1, Kuala Lumpur, 590004
  • Filer categoryNon-accelerated filer, Smaller reporting company4

See how the biggest companies compare on our leaderboards

OpGen (United States) image from its website
Image: opgen.com3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

79.6%Operating margin5
78.2%Net margin5
481.2%Revenue growth, 20255
74.1%Return on equity5
-$1.2MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development0¢$6.6K
  • Other costs19¢$5.7M
  • Interest0¢$11.2K
  • Income tax3¢$813.8K
  • Profit78¢$23.6M

Out of $30.2M in revenue.5

Financial statements

Revenue67895$30.2M in 2025+763% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $3.5M$3.5M20192020: $4.2M$4.2M2020+20%2021: $4.3M$4.3M2021+2%2022: $2.6M$2.6M2022−39%2023: $3.4M$3.4M2023+31%2024: $5.2M$5.2M2024+52%2025: $30.2M$30.2M2025+481%
Operating income6710895$24.0M in 2025
-$40.0M-$20.0M0$20.0M$40.0M2019: -$12.3M-$12.3M20192020: -$22.7M-$22.7M2020+85%2021: -$23.3M-$23.3M2021+2%2022: -$34.6M-$34.6M2022+49%2023: -$30.7M-$30.7M2023−11%2024: $324.7K$324.7K20242025: $24.0M$24.0M2025+7300%
Net income6710895$23.6M in 2025
-$40.0M-$20.0M0$20.0M$40.0M2019: -$12.4M-$12.4M20192020: -$26.2M-$26.2M2020+111%2021: -$34.8M-$34.8M2021+33%2022: -$37.3M-$37.3M2022+7%2023: -$32.7M-$32.7M2023−12%2024: $12.0M$12.0M20242025: $23.6M$23.6M2025+97%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Total revenue$30.2M$5.2M
Cost of products sold$31.6K
Cost of services$3.0M$1.6K
Research and development, net$6.6K$48.8K
General and administrative$3.1M$4.5M
Sales and marketing$12.4K$172.2K
Loss on deconsolidation of subsidiaries$75.1K
Total operating expenses$6.2M$4.9M
Operating income$24.0M$324.7K
Interest and other income, net$416.9K$371.4K
Interest expense-$11.2K-$7.6K
Gain on extinguishment of debt$9.7M
Gain on impairment adjustment$2.1M
Gain on settlement of compensation expenses$570.8K
Change in fair value of EIB loan guaranty-$908.6K
Foreign currency transaction gains$103$575
Total other income$405.8K$11.8M
Income before income taxes$24.4M$12.2M
Provision for income taxes-$813.8K-$176.7K
Net income$23.6M$12.0M
Net income allocated to preferred stockholders - basic-$141.3K-$636.7K
Net income available to common stockholders - basic$23.5M$11.4M
Net income allocated to preferred stockholders - diluted-$140.6K
Net income available to common stockholders - diluted$23.5M$12.0M
Basic$2.33$2.44
Diluted$2.32$2.30
Basic10.1M shares4.7M shares
Diluted10.1M shares5.2M shares
Other comprehensive income - foreign currency translation$2.3K
Comprehensive income$23.6M$12.0M

Compare OpGen (United States) with another company

Leadership

Who has led OpGen (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Oliver Schacht2020–2023
  2. David E. Lazar2024
  3. Christian-Laurent Bonte2025–now

President

  1. Kevin Krenitsky2015–2016

Chief financial officer

  1. Timothy C. Dec2015–2021

Chief operating officer

  1. Johannes Bacher2020–2023
  2. Mohd Azham Azudin2024–now
20052010201520202025
Board members and other officers (24)

Former names

  • OPGEN INCJun 14, 2004 to Feb 6, 20264

Timeline

  1. Dec 10, 2025New chief executive Christian-Laurent Bonte becomes CEO13
  2. Apr 3, 2024New chief executive David E. Lazar becomes CEO14
  3. Apr 10, 2020New chief executive Oliver Schacht becomes CEO15
  4. 2002Founded Founded1

Filings

255 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 79 major events, 65 insider forms, 7 large holders, 1 private raises, 82 other. The latest 20:

  1. Aug 19, 202610-Q EDGAR
  2. Aug 14, 2026NT 10-Q EDGAR
  3. Jul 6, 20264 EDGAR
  4. Jul 6, 20264 EDGAR
  5. Jul 6, 20264 EDGAR
  6. Jul 6, 20264 EDGAR
  7. Jul 6, 20264 EDGAR
  8. Jul 6, 20264 EDGAR
  9. Jun 12, 202610-Q EDGAR
  10. May 26, 202610-K EDGAR
  11. May 15, 2026NT 10-Q EDGAR
  12. Mar 31, 2026NT 10-K EDGAR
  13. Feb 27, 20268-K EDGAR
  14. Feb 6, 2026DEF 14A EDGAR
  15. Jan 26, 2026PRE 14A EDGAR
  16. Jan 16, 20268-K EDGAR
  17. Dec 23, 20258-K EDGAR
  18. Dec 10, 20253 EDGAR
  19. Dec 5, 20258-K EDGAR
  20. Nov 19, 202510-Q EDGAR

The 255 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 7 such filings since October 2021:

  1. Oct 24, 2024SCHEDULE 13D
  2. Sep 24, 2024SCHEDULE 13G/A
  3. Sep 20, 2024SCHEDULE 13G
  4. Aug 1, 2024SC 13D/A
  5. Apr 25, 2024SC 13D/A
  6. Apr 8, 2024SC 13D/A
  7. Apr 1, 2024SC 13D

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 3, 2022Raised $3.4 million in a private offering of equity Form D: 1 investor so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41